{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:19:56Z","timestamp":1792887596946,"version":"4.5.0"},"reference-count":224,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15663","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:28:09Z","timestamp":1779280089000},"page":"1-16","source":"Crossref","is-referenced-by-count":1,"title":["Targeting non\u2011small cell lung cancer:\u00a0Molecular mechanisms and clinical studies (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"Ying","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Respiratory Disease, Traditional Chinese Medicine Hospital of Jiang An County, Yibin, Sichuan 644200, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Traditional Chinese Medicine Hospital of Jiang An County, Yibin, Sichuan 644200, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyu","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, People's Hospital of Xu Yong County, Luzhou, Sichuan 646400, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"key20260619091750_b1-ol-32-1-15663","article-title":"Small Cell Lung Cancer","volume-title":"StatPearls","author":"Pincott","year":"2026"},{"key":"key20260619091750_b2-ol-32-1-15663","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20260619091750_b3-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/cac2.12627","article-title":"Cancer situation in China: An analysis based on the global epidemiological data released in 2024","volume":"45","author":"Diao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"key20260619091750_b4-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/his.15076","article-title":"Pulmonary squamous cell carcinoma and lymphoepithelial carcinoma-morphology, molecular characteristics and differential diagnosis","volume":"84","author":"Berezowska","year":"2024","journal-title":"Histopathology"},{"key":"key20260619091750_b5-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","article-title":"Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics","volume":"10","author":"Padinharayil","year":"2023","journal-title":"Genes Dis"},{"key":"key20260619091750_b6-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist Updat"},{"key":"key20260619091750_b7-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"key20260619091750_b8-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New dimensions","volume":"40","author":"Hanahan","year":"2022","journal-title":"Cancer Discovery"},{"key":"key20260619091750_b9-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: Current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"key20260619091750_b10-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"100015","DOI":"10.1016\/j.cellin.2022.100015","article-title":"Current therapy and development of therapeutic agents for lung cancer","volume":"1","author":"Wang","year":"2022","journal-title":"Cell Insight"},{"key":"key20260619091750_b11-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"102845","DOI":"10.1016\/j.ctrv.2024.102845","article-title":"Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives","volume":"131","author":"Parisi","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"key20260619091750_b12-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/s41416-020-01069-z","article-title":"The current treatment landscape in the UK for stage III NSCLC","volume":"123","author":"Evison","year":"2020","journal-title":"Br J Cancer"},{"key":"key20260619091750_b13-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of non-small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"key20260619091750_b14-ol-32-1-15663","first-page":"3659","article-title":"Inactivation of LKB1\/STK11 is a common event in adenocarcinomas of the lung","volume":"62","author":"Sanchez-Cespedes","year":"2002","journal-title":"Cancer Res"},{"key":"key20260619091750_b15-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research and Network","year":"2014","journal-title":"Nature"},{"key":"key20260619091750_b16-ol-32-1-15663","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"key20260619091750_b17-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"a037812","DOI":"10.1101\/cshperspect.a037812","article-title":"Molecular pathology of lung cancer","volume":"12","author":"J Saller","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"key20260619091750_b18-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.neo.2016.07.010","article-title":"Clinical genotyping of non-small cell lung cancers using targeted next-generation sequencing: Utility of identifying rare and co-mutations in oncogenic driver genes","volume":"18","author":"Tafe","year":"2016","journal-title":"Neoplasia"},{"key":"key20260619091750_b19-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J Cell Sci"},{"key":"key20260619091750_b20-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"key20260619091750_b21-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41556-022-01049-w","article-title":"Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth","volume":"25","author":"Tang","year":"2023","journal-title":"Nat Cell Biol"},{"key":"key20260619091750_b22-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"key20260619091750_b23-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.3390\/cancers14215430","article-title":"KRAS in NSCLC: State of the art and future perspectives","volume":"14","author":"Cascetta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260619091750_b24-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: Recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Ann Oncol"},{"key":"key20260619091750_b25-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrm1105","article-title":"Ras proteins: Different signals from different locations","volume":"4","author":"Hancock","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20260619091750_b26-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-Mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b27-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.lungcan.2019.01.003","article-title":"Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11","volume":"130","author":"La Fleur","year":"2019","journal-title":"Lung Cancer"},{"key":"key20260619091750_b28-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"key20260619091750_b29-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/mc.23908","article-title":"Differential Response and Resistance to KRAS-Targeted Therapy","volume":"64","author":"Liu","year":"2025","journal-title":"Mol Carcinog"},{"key":"key20260619091750_b30-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1023\/A:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","volume":"8","author":"Voldborg","year":"1997","journal-title":"Ann Oncol"},{"key":"key20260619091750_b31-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.acr.2020.04.003","article-title":"EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells","volume":"147","author":"Talukdar","year":"2020","journal-title":"Adv Cancer Res"},{"key":"key20260619091750_b32-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260619091750_b33-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0163-7258(98)00045-X","article-title":"The epidermal growth factor receptor and its inhibition in cancer therapy","volume":"82","author":"Woodburn","year":"1999","journal-title":"Pharmacol Ther"},{"key":"key20260619091750_b34-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1200\/JCO.2007.12.1178","article-title":"Structure and clinical relevance of the epidermal growth factor receptor in human cancer","volume":"26","author":"Kumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20260619091750_b35-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41392-022-01200-x","article-title":"Signaling pathways and targeted therapies in lung squamous cell carcinoma: Mechanisms and clinical trials","volume":"7","author":"Niu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"key20260619091750_b36-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260619091750_b37-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3892\/ol.2025.15121","article-title":"EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review)","volume":"30","author":"Tian","year":"2025","journal-title":"Oncol Lett"},{"key":"key20260619091750_b38-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2574526","DOI":"10.1080\/07853890.2025.2574526","article-title":"Precision navigation through the labyrinth: Overcoming EGFR resistance in non-small cell lung cancer","volume":"57","author":"Wang","year":"2025","journal-title":"Ann Med"},{"key":"key20260619091750_b39-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"e70921","DOI":"10.1002\/cam4.70921","article-title":"Strategies beyond 3rd EGFR-TKI acquired resistance: Opportunities and challenges","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med"},{"key":"key20260619091750_b40-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"100395","DOI":"10.1016\/j.esmoop.2022.100482","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"key":"key20260619091750_b41-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"403","DOI":"10.7150\/jca.11424","article-title":"Multiplex ligation-dependent probe amplification can clarify HER2 status in gastric cancers with \u2018Polysomy 17\u2019","volume":"6","author":"Wang","year":"2015","journal-title":"J Cancer"},{"key":"key20260619091750_b42-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"107385","DOI":"10.1016\/j.lungcan.2023.107385","article-title":"Management of HER2 alterations in non-small cell lung cancer-the past, present, and future","volume":"186","author":"Nutzinger","year":"2023","journal-title":"Lung Cancer"},{"key":"key20260619091750_b43-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210478","article-title":"The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"key20260619091750_b44-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev.biophys.37.032807.125829","article-title":"Structure-based view of epidermal growth factor receptor regulation","volume":"37","author":"Ferguson","year":"2008","journal-title":"Annu Rev Biophys"},{"key":"key20260619091750_b45-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"key20260619091750_b46-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"100260","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): A glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open"},{"key":"key20260619091750_b47-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"key20260619091750_b48-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.3390\/molecules30122645","article-title":"HER2 in non-small cell lung cancer (NSCLC): Evolution of the therapeutic landscape and emerging drugs-A long way to the top","volume":"30","author":"Trillo Aliaga","year":"2025","journal-title":"Molecules"},{"key":"key20260619091750_b49-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1038\/sj.onc.1204594","article-title":"Translocations involving anaplastic lymphoma kinase (ALK)","volume":"20","author":"Duyster","year":"2001","journal-title":"Oncogene"},{"key":"key20260619091750_b50-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"key":"key20260619091750_b51-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20260619091750_b52-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.rcl.2018.01.012","article-title":"Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer","volume":"56","author":"Shroff","year":"2018","journal-title":"Radiol Clin North Am"},{"key":"key20260619091750_b53-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.3390\/curroncol30050384","article-title":"Sustained improvement in the management of patients with non-small-cell lung cancer (NSCLC) harboring ALK translocation: where are we running?","volume":"30","author":"Spitaleri","year":"2023","journal-title":"Curr Oncol"},{"key":"key20260619091750_b54-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20260619091750_b55-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b56-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","article-title":"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20260619091750_b57-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/cancers14051184","article-title":"Review of therapeutic strategies for anaplastic lymphoma kinase-rearranged non-small cell lung cancer","volume":"14","author":"Fukui","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260619091750_b58-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12524","article-title":"Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study","volume":"44","author":"Zheng","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"key20260619091750_b59-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"key20260619091750_b60-ol-32-1-15663","article-title":"MET exon 14 skipping mutations in non-small-cell lung cancer: An Overview of biology, clinical outcomes, and testing considerations","volume":"5","author":"Socinski","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"key20260619091750_b61-ol-32-1-15663","first-page":"820","article-title":"MET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of \u201840 years of wilderness\u2019 and into a clear path of regulatory approval","volume":"4","author":"Reungwetwattana","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"key20260619091750_b62-ol-32-1-15663","article-title":"Characterization of Non-small-cell lung cancers with met exon 14 skipping alterations detected in tissue or liquid: Clinicogenomics and real-world treatment patterns","volume":"5","author":"Lee","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"key20260619091750_b63-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20260619091750_b64-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/jclinpath-2015-203050","article-title":"Gene of the month: MET","volume":"68","author":"Skead","year":"2015","journal-title":"J Clin Pathol"},{"key":"key20260619091750_b65-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1021\/jm401427c","article-title":"Targeting receptor tyrosine kinase MET in cancer: Small molecule inhibitors and clinical progress","volume":"57","author":"Cui","year":"2014","journal-title":"J Med Chem"},{"key":"key20260619091750_b66-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc Enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"key20260619091750_b67-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20260619091750_b68-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/0008-5472.CAN-11-3990","article-title":"The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation","volume":"72","author":"Jun","year":"2012","journal-title":"Cancer Res"},{"key":"key20260619091750_b69-ol-32-1-15663","first-page":"156","article-title":"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer","volume":"4","author":"Kohno","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"key20260619091750_b70-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1158\/1078-0432.CCR-12-0550","article-title":"Identifying and targeting ROS1 gene fusions in non-small cell lung cancer","volume":"18","author":"Davies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b71-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1158\/0008-5472.CAN-06-1193","article-title":"ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2\/phosphatidylinositol 3-kinase\/mammalian target of rapamycin signaling axis to form glioblastoma in mice","volume":"66","author":"Charest","year":"2006","journal-title":"Cancer Res"},{"key":"key20260619091750_b72-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b73-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: Management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"key20260619091750_b74-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jtho.2019.03.022","article-title":"Advanced-stage non-small cell lung cancer: Advances in thoracic oncology 2018","volume":"14","author":"Remon","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key20260619091750_b75-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"key20260619091750_b76-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1759-7714.12917","article-title":"PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1","volume":"10","author":"Lee","year":"2019","journal-title":"Thorac Cancer"},{"key":"key20260619091750_b77-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"e18726","DOI":"10.1097\/MD.0000000000018726","article-title":"Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma","volume":"99","author":"Bylicki","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"key20260619091750_b78-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"key20260619091750_b79-ol-32-1-15663","first-page":"583929","article-title":"TP53 mutations in nonsmall cell lung cancer","volume":"2011","author":"Mogi","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"key20260619091750_b80-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/278261a0","article-title":"T antigen is bound to a host protein in SV40 transformed cells","volume":"278","author":"Lane","year":"1979","journal-title":"Nature"},{"key":"key20260619091750_b81-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nrm2395","article-title":"Transcriptional control of human p53-regulated genes","volume":"9","author":"Riley","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20260619091750_b82-ol-32-1-15663","first-page":"743","article-title":"Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation","volume":"7","author":"Bodner","year":"1992","journal-title":"Oncogene"},{"key":"key20260619091750_b83-ol-32-1-15663","first-page":"135","article-title":"Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions","volume":"55","author":"Sozzi","year":"1995","journal-title":"Cancer Res"},{"key":"key20260619091750_b84-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0300-9084(01)01356-6","article-title":"TP53: A key gene in human cancer","volume":"84","author":"Guimaraes","year":"2002","journal-title":"Biochimie"},{"key":"key20260619091750_b85-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"147","DOI":"10.31083\/j.fbl2807147","article-title":"TP53 exon 5 mutation indicates poor progression-free survival for patients with stage IV NSCLC","volume":"28","author":"Feng","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"key":"key20260619091750_b86-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/ng0198-38","article-title":"Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase","volume":"18","author":"Jenne","year":"1998","journal-title":"Nat Genet"},{"key":"key20260619091750_b87-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/34432","article-title":"A serine\/threonine kinase gene defective in Peutz-Jeghers syndrome","volume":"391","author":"Hemminki","year":"1998","journal-title":"Nature"},{"key":"key20260619091750_b88-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"106757","DOI":"10.1016\/j.phrs.2023.106757","article-title":"LKB1 signaling and patient survival outcomes in hepatocellular carcinoma","volume":"192","author":"Nguyen","year":"2023","journal-title":"Pharmacol Res"},{"key":"key20260619091750_b89-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/humu.20222","article-title":"Mutations in the human LKB1\/STK11 gene","volume":"26","author":"Launonen","year":"2005","journal-title":"Hum Mutat"},{"key":"key20260619091750_b90-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"8730816","DOI":"10.1155\/2019\/8730816","article-title":"LKB1\/AMPK pathway and drug response in cancer: A therapeutic perspective","volume":"2019","author":"Ciccarese","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"key20260619091750_b91-ol-32-1-15663","first-page":"e21078","article-title":"Unraveling the role of STK11\/LKB1 in non-small cell lung cancer","volume":"14","author":"Sumbly","year":"2022","journal-title":"Cureus"},{"key":"key20260619091750_b92-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/diagnostics11020196","article-title":"The importance of STK11\/LKB1 assessment in non-small cell lung carcinomas","volume":"11","author":"Mograbi","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"key20260619091750_b93-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"key20260619091750_b94-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"S3028","DOI":"10.1200\/JCO.2018.36.15_suppl.3028","article-title":"Somatic STK11\/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC","volume":"36","author":"Jure-Kunkel","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20260619091750_b95-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.redox.2023.102726","article-title":"The KEAP1-NRF2 pathway: Targets for therapy and role in cancer","volume":"63","author":"Adinolfi","year":"2023","journal-title":"Redox Biol"},{"key":"key20260619091750_b96-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"7130","DOI":"10.1128\/MCB.24.16.7130-7139.2004","article-title":"Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2","volume":"24","author":"Kobayashi","year":"2004","journal-title":"Mol Cell Biol"},{"key":"key20260619091750_b97-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1046\/j.1365-2443.2003.00640.x","article-title":"Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles","volume":"8","author":"Itoh","year":"2003","journal-title":"Genes Cells"},{"key":"key20260619091750_b98-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1249237","DOI":"10.3389\/fonc.2023.1249237","article-title":"Metabolic barriers in non-small cell lung cancer with LKB1 and\/or KEAP1 mutations for immunotherapeutic strategies","volume":"13","author":"Tanaka","year":"2023","journal-title":"Front Oncol"},{"key":"key20260619091750_b99-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jtho.2022.03.011","article-title":"KEAP1-Mutant NSCLC: The catastrophic failure of a cell-protecting Hub","volume":"17","author":"Scalera","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20260619091750_b100-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"15259","DOI":"10.1073\/pnas.1305687110","article-title":"Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex","volume":"110","author":"Baird","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20260619091750_b101-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2021.07.006","article-title":"KEAP1\/NRF2 (NFE2L2) mutations in NSCLC-Fuel for a superresistant phenotype?","volume":"159","author":"Dempke","year":"2021","journal-title":"Lung Cancer"},{"key":"key20260619091750_b102-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"e00099","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol Cell Biol"},{"key":"key20260619091750_b103-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/jclinpath-2018-205216","article-title":"p16","volume":"71","author":"Serra","year":"2018","journal-title":"J Clin Pathol"},{"key":"key20260619091750_b104-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1878-0261.13206","article-title":"Co-occurrence of CDKN2A\/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma","volume":"16","author":"Peng","year":"2022","journal-title":"Mol Oncol"},{"key":"key20260619091750_b105-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/26155","article-title":"Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a","volume":"395","author":"Russo","year":"1998","journal-title":"Nature"},{"key":"key20260619091750_b106-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/excr.1997.3824","article-title":"The tumor suppressor protein p16INK4a","volume":"237","author":"Serrano","year":"1997","journal-title":"Exp Cell Res"},{"key":"key20260619091750_b107-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/CAD.0000000000001620","article-title":"CDKN2A inhibited ferroptosis through activating JAK2\/STAT3 pathway to modulate cisplatin resistance in cervical squamous cell carcinoma","volume":"35","author":"Yong","year":"2024","journal-title":"Anticancer Drugs"},{"key":"key20260619091750_b108-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.62347\/RLVZ6860","article-title":"NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K\/AKT signaling pathway","volume":"14","author":"Wang","year":"2024","journal-title":"Am J Cancer Res"},{"key":"key20260619091750_b109-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"e54970","DOI":"10.1371\/journal.pone.0054970","article-title":"The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: A systematic review and meta-analysis","volume":"8","author":"Lou-Qian","year":"2013","journal-title":"PLoS One"},{"key":"key20260619091750_b110-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1038\/s41598-021-99524-1","article-title":"CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer","volume":"11","author":"Gutiontov","year":"2021","journal-title":"Sci Rep"},{"key":"key20260619091750_b111-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2019.02.002","article-title":"PIK3CA in cancer: The past 30 years","volume":"59","author":"Arafeh","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"key20260619091750_b112-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"key20260619091750_b113-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat Cancer"},{"key":"key20260619091750_b114-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1158\/0008-5472.CAN-07-5084","article-title":"PIK3CA mutations and copy number gains in human lung cancers","volume":"68","author":"Yamamoto","year":"2008","journal-title":"Cancer Res"},{"key":"key20260619091750_b115-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semcancer.2019.02.001","article-title":"Mechanisms of PTEN loss in cancer: It's all about diversity","volume":"59","author":"Alvarez-Garcia","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"key20260619091750_b116-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2741\/3815","article-title":"Kinase-driven pathways of EGFR in lung carcinomas: Perspectives on targeting therapy","volume":"16","author":"Dobashi","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"key":"key20260619091750_b117-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12943-024-02157-x","article-title":"The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS(G12D)-driven non-small cell lung cancer","volume":"23","author":"McDaid","year":"2024","journal-title":"Mol Cancer"},{"key":"key20260619091750_b118-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"key20260619091750_b119-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol Cancer"},{"key":"key20260619091750_b120-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"key20260619091750_b121-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"key20260619091750_b122-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: Discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260619091750_b123-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.3390\/ijms241713618","article-title":"Targeted therapy for cancers: From ongoing clinical trials to FDA-Approved drugs","volume":"24","author":"Choi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260619091750_b124-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"key20260619091750_b125-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"key20260619091750_b126-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"key20260619091750_b127-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/ATVBAHA.108.179663","article-title":"Vascular endothelial growth factor","volume":"29","author":"Ferrara","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20260619091750_b128-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/10739680802095964","article-title":"Systems biology of vascular endothelial growth factors","volume":"15","author":"Gabhann","year":"2008","journal-title":"Microcirculation"},{"key":"key20260619091750_b129-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.semcancer.2009.05.003","article-title":"The angiogenic switch in carcinogenesis","volume":"19","author":"Baeriswyl","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"key20260619091750_b130-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/biom14070741","article-title":"Lumbrokinase extracted from earthworms synergizes with bevacizumab and chemotherapeutics in treating non-small cell lung cancer by targeted inactivation of BPTF\/VEGF and NF-\u0138B\/COX-2 signaling","volume":"14","author":"Hua","year":"2024","journal-title":"Biomolecules"},{"key":"key20260619091750_b131-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"8863","DOI":"10.3390\/ijms23168863","article-title":"Anti-Angiogenic therapy in ALK rearranged non-small cell lung cancer (NSCLC)","volume":"23","author":"Tan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20260619091750_b132-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/1061186X.2025.2508985","article-title":"Revisiting VEGF\/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: Where are we and where should we go?","volume":"33","author":"Yao","year":"2025","journal-title":"J Drug Target"},{"key":"key20260619091750_b133-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res"},{"key":"key20260619091750_b134-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20260619091750_b135-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/bfgp\/elab038","article-title":"Potential therapeutic targets of Klebsiella pneumoniae: A multi-omics review perspective","volume":"21","author":"Ali","year":"2022","journal-title":"Brief Funct Genomics"},{"key":"key20260619091750_b136-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.biocel.2008.04.009","article-title":"The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells","volume":"40","author":"Ramos","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"key20260619091750_b137-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1517\/14656566.2013.770475","article-title":"Trametinib (GSK1120212) in the treatment of melanoma","volume":"14","author":"Salama","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"key20260619091750_b138-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"704","DOI":"10.7150\/thno.80184","article-title":"Battles against aberrant KEAP1-NRF2 signaling in lung cancer: Intertwined metabolic and immune networks","volume":"13","author":"Xu","year":"2023","journal-title":"Theranostics"},{"key":"key20260619091750_b139-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"746e4","DOI":"10.1016\/j.celrep.2019.06.047","article-title":"molecular mechanism of cellular oxidative stress sensing by Keap1","volume":"28","author":"Suzuki","year":"2019","journal-title":"Cell Rep"},{"key":"key20260619091750_b140-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"14841","DOI":"10.1074\/jbc.M513737200","article-title":"Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2","volume":"281","author":"Salazar","year":"2006","journal-title":"J Biol Chem"},{"key":"key20260619091750_b141-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s43018-020-0071-1","article-title":"Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1","volume":"1","author":"Romero","year":"2020","journal-title":"Nat Cancer"},{"key":"key20260619091750_b142-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"102649","DOI":"10.1016\/j.isci.2021.102649","article-title":"KEAP1 deficiency drives glucose dependency and sensitizes lung cancer cells and tumors to GLUT inhibition","volume":"24","author":"Koppula","year":"2021","journal-title":"iScience"},{"key":"key20260619091750_b143-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"102358","DOI":"10.1016\/j.redox.2022.102358","article-title":"A CRISPR screen identifies redox vulnerabilities for KEAP1\/NRF2 mutant non-small cell lung cancer","volume":"54","author":"Jiang","year":"2022","journal-title":"Redox Biol"},{"key":"key20260619091750_b144-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","article-title":"Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-Deficient NSCLC tumors","volume":"11","author":"Singh","year":"2016","journal-title":"ACS Chem Biol"},{"key":"key20260619091750_b145-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/1078-0432.CCR-20-2859","article-title":"STK11\/LKB1 mutations in NSCLC are associated with KEAP1\/NRF2-Dependent radiotherapy resistance targetable by glutaminase inhibition","volume":"27","author":"Sitthideatphaiboon","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b146-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4046\/trd.2024.0087","article-title":"KEAP1-NRF2 pathway as a novel therapeutic target for EGFR-Mutant non-small cell lung cancer","volume":"88","author":"Choi","year":"2025","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"key20260619091750_b147-ol-32-1-15663","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"key20260619091750_b148-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"102807","DOI":"10.1016\/j.ctrv.2024.102807","article-title":"Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape","volume":"130","author":"Weller","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"key20260619091750_b149-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"key20260619091750_b150-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key20260619091750_b151-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.04.017","article-title":"Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06)","volume":"121","author":"Locher","year":"2018","journal-title":"Lung Cancer"},{"key":"key20260619091750_b152-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1056\/NEJM199010043231403","article-title":"A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer","volume":"323","author":"Dillman","year":"1990","journal-title":"N Engl J Med"},{"key":"key20260619091750_b153-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12957-018-1313-x","article-title":"Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A\/N2 non-small cell lung cancer: A meta-analysis","volume":"16","author":"Chen","year":"2018","journal-title":"World J Surg Oncol"},{"key":"key20260619091750_b154-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: State of the art and future directions","volume":"44","author":"Miao","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"key20260619091750_b155-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): An open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20260619091750_b156-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"240047","DOI":"10.1183\/20734735.0047-2024","article-title":"Stage III NSCLC treatment options: Too many choices","volume":"20","author":"Asmara","year":"2024","journal-title":"Breathe (Sheff)"},{"key":"key20260619091750_b157-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13148-025-01961-6","article-title":"Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms","volume":"17","author":"Yu","year":"2025","journal-title":"Clin Epigenetics"},{"key":"key20260619091750_b158-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20260619091750_b159-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"key20260619091750_b160-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"111684","DOI":"10.1016\/j.intimp.2024.111684","article-title":"Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma","volume":"129","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"key20260619091750_b161-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jtho.2016.03.012","article-title":"Scientific advances in lung cancer 2015","volume":"11","author":"Tsao","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20260619091750_b162-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20260619091750_b163-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/cas.16437","article-title":"Osimertinib for EGFR-Mutant NSCLC patients with acquired T790M and EGFR amplification after first-generation EGFR-TKI resistance","volume":"116","author":"Zhang","year":"2025","journal-title":"Cancer Sci"},{"key":"key20260619091750_b164-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK Inhibitors in ALK-Rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"key20260619091750_b165-ol-32-1-15663","first-page":"609","article-title":"Progress on Mechanism of MET gene mutation and targeted drugs in non-small cell lung cancer","volume":"23","author":"Han","year":"2020","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"key20260619091750_b166-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA Approval summary: Capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET Exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b167-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"key20260619091750_b168-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: Primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"key":"key20260619091750_b169-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/vaccines13020128","article-title":"Emerging immunotherapies for advanced non-small-cell lung cancer","volume":"13","author":"Wolf","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"key20260619091750_b170-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20260619091750_b171-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-13-0731","article-title":"New strategies in lung cancer: Translating immunotherapy into clinical practice","volume":"20","author":"Forde","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b172-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: Treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260619091750_b173-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: From mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260619091750_b174-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov"},{"key":"key20260619091750_b175-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1038\/s41467-025-60281-8","article-title":"TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: A first-in-human phase I\/II dose-escalation study","volume":"16","author":"Emmers","year":"2025","journal-title":"Nat Commun"},{"key":"key20260619091750_b176-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-Mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"key20260619091750_b177-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/2159-8290.CD-18-1286","article-title":"Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-Mutant lung cancers","volume":"9","author":"Della Corte","year":"2019","journal-title":"Cancer Discov"},{"key":"key20260619091750_b178-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","article-title":"Role of mast cells in shaping the tumor microenvironment","volume":"58","author":"Komi","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"key20260619091750_b179-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"842960","DOI":"10.3389\/fonc.2022.842960","article-title":"Novel angiogenic regulators and anti-angiogenesis drugs targeting angiogenesis signaling pathways: Perspectives for targeting angiogenesis in lung cancer","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"key20260619091750_b180-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"10732748241270589","DOI":"10.1177\/10732748241270589","article-title":"Advances in predictive biomarkers for anti-angiogenic therapy in non-small cell lung cancer","volume":"31","author":"Zhao","year":"2024","journal-title":"Cancer Control"},{"key":"key20260619091750_b181-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s40425-019-0812-9","article-title":"Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20260619091750_b182-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.21037\/tlcr-20-552","article-title":"Combining radiotherapy with targeted therapies in non-small cell lung cancer: Focus on anti-EGFR, anti-ALK and anti-angiogenic agents","volume":"10","author":"Wrona","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"key20260619091750_b183-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2023.10.022","article-title":"Emerging applications of anti-angiogenic nanomaterials in oncotherapy","volume":"364","author":"Tang","year":"2023","journal-title":"J Control Release"},{"key":"key20260619091750_b184-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"835680","DOI":"10.1155\/2010\/835680","article-title":"Molecular mechanisms of resistance to tumour anti-angiogenic strategies","volume":"2010","author":"Grepin","year":"2010","journal-title":"J Oncol"},{"key":"key20260619091750_b185-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12272-025-01539-z","article-title":"The inhibition of endothelial DLL4-NOTCH1 signaling by 2\u2032-hydroxyflavanone enhances anti-PD-1 therapy in melanoma","volume":"48","author":"You","year":"2025","journal-title":"Arch Pharm Res"},{"key":"key20260619091750_b186-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat Med"},{"key":"key20260619091750_b187-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"key":"key20260619091750_b188-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-Mutated non-small cell lung cancer","volume":"12","author":"Janne","year":"2022","journal-title":"Cancer Discov"},{"key":"key20260619091750_b189-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"key20260619091750_b190-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.annonc.2024.03.004","article-title":"New ADCs bring new questions in EGFR NSCLC and beyond","volume":"35","author":"Scott","year":"2024","journal-title":"Ann Oncol"},{"key":"key20260619091750_b191-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260619091750_b192-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: A Randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"key20260619091750_b193-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"key":"key20260619091750_b194-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"e002531","DOI":"10.1136\/jitc-2021-002531","article-title":"Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations","volume":"9","author":"Li","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20260619091750_b195-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1010e11","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"key20260619091750_b196-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"120760","DOI":"10.1016\/j.biomaterials.2021.120760","article-title":"Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy","volume":"271","author":"Jang","year":"2021","journal-title":"Biomaterials"},{"key":"key20260619091750_b197-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.7150\/thno.103372","article-title":"Bispecific Siglec-15\/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors in vivo","volume":"15","author":"Shen","year":"2025","journal-title":"Theranostics"},{"key":"key20260619091750_b198-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"7752","DOI":"10.2174\/0109298673347323241119184648","article-title":"Novel strategies for the treatment of lung cancer: An in-depth analysis of the use of immunotherapy, precision medicine, and artificial intelligence to improve prognoses","volume":"32","author":"Kedar","year":"2025","journal-title":"Curr Med Chem"},{"key":"key20260619091750_b199-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41698-025-00986-7","article-title":"Progress and challenges of artificial intelligence in lung cancer clinical translation","volume":"9","author":"Zhu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"key20260619091750_b200-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-24-2310","article-title":"Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial","volume":"31","author":"Negrao","year":"2025","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b201-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1158\/2767-9764.CRC-24-0153","article-title":"Loss of STK11 suppresses lipid metabolism and attenuates KRAS-induced immunogenicity in patients with non-small cell lung cancer","volume":"4","author":"Principe","year":"2024","journal-title":"Cancer Res Commun"},{"key":"key20260619091750_b202-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"key20260619091750_b203-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"key20260619091750_b204-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/1078-0432.CCR-21-2049","article-title":"Inactivation of AMPK leads to attenuation of antigen presentation and immune evasion in lung adenocarcinoma","volume":"28","author":"Gao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20260619091750_b205-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41467-024-46166-2","article-title":"TBC1D23 mediates Golgi-specific LKB1 signaling","volume":"15","author":"Tu","year":"2024","journal-title":"Nat Commun"},{"key":"key20260619091750_b206-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-cellbio-120420-094431","article-title":"The AMPK pathway: Molecular rejuvenation of metabolism and mitochondria","volume":"41","author":"Malik","year":"2025","journal-title":"Annu Rev Cell Dev Biol"},{"key":"key20260619091750_b207-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/0008-5472.CAN-22-1740","article-title":"PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer","volume":"83","author":"Long","year":"2023","journal-title":"Cancer Res"},{"key":"key20260619091750_b208-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-Driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"key":"key20260619091750_b209-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3390\/cancers16101818","article-title":"LKB1 loss correlates with STING loss and, in cooperation with beta-catenin membranous loss, indicates poor prognosis in patients with operable non-small cell lung cancer","volume":"16","author":"Lagoudaki","year":"2024","journal-title":"Cancers (Basel)"},{"key":"key20260619091750_b210-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jtho.2023.07.020","article-title":"STK11\/LKB1-deficient phenotype rather than mutation diminishes immunotherapy efficacy and represents STING\/Type I interferon\/CD8(+) T-cell dysfunction in NSCLC","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"key":"key20260619091750_b211-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.4049\/jimmunol.1100367","article-title":"The liver kinase B1 is a central regulator of T cell development, activation, and metabolism","volume":"187","author":"MacIver","year":"2011","journal-title":"J Immunol"},{"key":"key20260619091750_b212-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"113579","DOI":"10.1016\/j.celrep.2023.113579","article-title":"LKB1 prevents ILC2 exhaustion to enhance antitumor immunity","volume":"43","author":"Niu","year":"2024","journal-title":"Cell Rep"},{"key":"key20260619091750_b213-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"874e6","DOI":"10.1016\/j.cmet.2022.04.003","article-title":"Glutaminase inhibition impairs CD8 T cell activation in STK11-\/Lkb1-deficient lung cancer","volume":"34","author":"Best","year":"2022","journal-title":"Cell Metab"},{"key":"key20260619091750_b214-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-023-02933-5","article-title":"Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy","volume":"43","author":"Ndembe","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260619091750_b215-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"889826","DOI":"10.3389\/fonc.2022.889826","article-title":"LKB1: Can we target an hidden target? Focus on NSCLC","volume":"12","author":"Ndembe","year":"2022","journal-title":"Front Oncol"},{"key":"key20260619091750_b216-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1038\/s41467-025-58753-y","article-title":"LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"key20260619091750_b217-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41419-023-05592-8","article-title":"Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors","volume":"14","author":"Bhatt","year":"2023","journal-title":"Cell Death Dis"},{"key":"key20260619091750_b218-ol-32-1-15663","article-title":"In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancer","author":"Deng","year":"2023","journal-title":"bioRxiv"},{"key":"key20260619091750_b219-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"10027","DOI":"10.1007\/s00432-023-04919-4","article-title":"To be, or not to be: The dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations","volume":"149","author":"Cai","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20260619091750_b220-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: A phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"key":"key20260619091750_b221-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s41467-023-36892-4","article-title":"CDK4\/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy","volume":"14","author":"Bai","year":"2023","journal-title":"Nat Commun"},{"key":"key20260619091750_b222-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/2326-6066.CIR-23-1075","article-title":"Hyper-responses and overcomes resistance to interferon sensitive influenza induces adaptive immune anti-PD-1 in murine non-small cell lung cancer","volume":"12","author":"Du","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"key20260619091750_b223-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/s41467-025-57297-5","article-title":"Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer","volume":"16","author":"Shu","year":"2025","journal-title":"Nat Commun"},{"key":"key20260619091750_b224-ol-32-1-15663","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1158\/0008-5472.CAN-25-4003","article-title":"Precision epigenetic reprogramming: CoREST inhibition sensitizes STK11-Mutant tumors to immune checkpoint blockade therapy","volume":"85","author":"Lin","year":"2025","journal-title":"Cancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:18:02Z","timestamp":1781849882000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,20]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15663","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}